S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:MRKR - TapImmune Stock Price, Forecast & News

$3.18
-0.02 (-0.63 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$3.13
Now: $3.18
$3.30
50-Day Range
$2.68
MA: $3.45
$4.26
52-Week Range
$2.61
Now: $3.18
$9.17
Volume227,827 shs
Average Volume469,179 shs
Market Capitalization$145.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRKR
CUSIPN/A
CIKN/A
Phone713-400-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210,000.00
Book Value$1.31 per share

Profitability

Net Income$-147,960,000.00

Miscellaneous

Employees11
Market Cap$145.39 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.


TapImmune (NASDAQ:MRKR) Frequently Asked Questions

What is TapImmune's stock symbol?

TapImmune trades on the NASDAQ under the ticker symbol "MRKR."

How were TapImmune's earnings last quarter?

TapImmune Inc. (NASDAQ:MRKR) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. View TapImmune's Earnings History.

When is TapImmune's next earnings date?

TapImmune is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for TapImmune.

What price target have analysts set for MRKR?

6 analysts have issued 12 month price targets for TapImmune's shares. Their forecasts range from $6.00 to $16.00. On average, they expect TapImmune's stock price to reach $10.72 in the next year. This suggests a possible upside of 236.9% from the stock's current price. View Analyst Price Targets for TapImmune.

What is the consensus analysts' recommendation for TapImmune?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TapImmune in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TapImmune.

What are Wall Street analysts saying about TapImmune stock?

Here are some recent quotes from research analysts about TapImmune stock:
  • 1. According to Zacks Investment Research, "Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States. " (10/10/2019)
  • 2. Nomura analysts commented, "Ph2 AML IND in 3Q19, Data update Pivotal (Accelerated Approval?). The trial will evaluate multiTAAs in post-aHSCT patients in both active and adjuvant settings. We believe post-transplant AML is a logical approach to rapid registration, given promising data to date and potential for accelerated approval. We see three key AML settings with registration potential: r/r post-transplant; MRD(-) post-transplant (taking advantage of the recent FDA guidance document. See also our initiation for more on MulitTAA potential in AML. Our View. MRKR presented data from the TACTOPS trial (NCT03192462, IST) testing MultiTAA in pancreatic cancer (see our note). We were encouraged by the results, noting the difficulty of pancreatic cancer as a solid tumor with low immunogenicity and fibrotic microenvironment." (8/13/2019)

Has TapImmune been receiving favorable news coverage?

Media coverage about MRKR stock has been trending somewhat negative on Thursday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TapImmune earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for TapImmune.

Are investors shorting TapImmune?

TapImmune saw a increase in short interest in November. As of November 29th, there was short interest totalling 5,050,000 shares, an increase of 9.1% from the November 14th total of 4,630,000 shares. Based on an average trading volume of 319,200 shares, the days-to-cover ratio is currently 15.8 days. Approximately 56.9% of the company's stock are sold short. View TapImmune's Current Options Chain.

Who are some of TapImmune's key competitors?

What other stocks do shareholders of TapImmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TapImmune investors own include Ionis Pharmaceuticals (IONS), Amarin (AMRN), CareDx (CDNA), Exelixis (EXEL), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Alibaba Group (BABA), Acasti Pharma (ACST) and ADMA Biologics (ADMA).

Who are TapImmune's key executives?

TapImmune's management team includes the folowing people:
  • Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 47)
  • Mr. Anthony H. Kim, Chief Financial Officer (Age 43)
  • Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 53)
  • Dr. Ann M. Leen, Chief Scientific Officer
  • Ms. Elizabeth Donnelly, Director of Admin.

How do I buy shares of TapImmune?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TapImmune's stock price today?

One share of MRKR stock can currently be purchased for approximately $3.18.

How big of a company is TapImmune?

TapImmune has a market capitalization of $145.39 million and generates $210,000.00 in revenue each year. The company earns $-147,960,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. TapImmune employs 11 workers across the globe.View Additional Information About TapImmune.

What is TapImmune's official website?

The official website for TapImmune is http://www.markertherapeutics.com/.

How can I contact TapImmune?

TapImmune's mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected]


MarketBeat Community Rating for TapImmune (NASDAQ MRKR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about TapImmune and other stocks. Vote "Outperform" if you believe MRKR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRKR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Discount Rate

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel